US FDA grants priority review to Roche’s Tecentriq as adjuvant treatment for non-small cell lung…
Tecentriq is the first and only cancer immunotherapy to demonstrate positive phase-III results in the adjuvant lung cancer setting…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.